Women aged 18–36 years with a body weight of more than 60 kg up to and including 90 kg, a BMI of 18–32 kg/m2, a menstrual cycle length of 24–35 days, access to ejaculatory sperm and an indication for controlled ovarian stimulation (COS) before IVF or ICSI were eligible to enroll in the study. Patients who had a (history of) an endocrine abnormality, an abnormal outcome of blood biochemistry or hematology, an abnormal cervical smear, a chronic disease, relevant ovarian-, tubal- or uterine-pathology that could interfere with the COS treatment (e.g. endometrioma >0 mm or fibroids ≥5 cm), embryo implantation or pregnancy were not to be included in the trial. Patients who had a history of ovarian hyperresponse (more than 30 follicles ≥11 mm) or ovarian hyperstimulation syndrome (OHSS), polycystic ovary syndrome (PCOS) or a basal antral follicle count (AFC) of more than 20 on ultrasound (<11 mm, both ovaries combined) were excluded from participation. Other exclusion criteria included a previously low ovarian response to FSH or hMG treatment (i.e. cycle cancelled due to insufficient ovarian response or less than four oocytes obtained), an FSH or LH over 12 IU/L in the early follicular phase, more than three consecutive unsuccessful IVF cycles since the last ongoing pregnancy, a history of recurrent miscarriage (three or more), or currently smoking more than five cigarettes per day.
>
Disorders
>
Disease or Syndrome
>
Ovarian Hyperstimulation Syndrome
Ovarian Hyperstimulation Syndrome
Ovarian Hyperstimulation Syndrome (OHSS) is a complication that can occur during fertility treatments involving the use of ovarian stimulation medications.
These medications are used to induce the development of multiple follicles, which can lead to the overproduction of estrogen and the release of large amounts of fluid into the abdominal cavity.
OHSS can range from mild to severe, with symptoms including abdominal pain, nausea, vomiting, and rapid weight gain.
In severe cases, it can lead to life-threatening complications such as kidney failure and thrombosis.
Careful monitoring and management of ovarian stimulation is crucial to prevent and minimize the risk of OHSS.
Researchers and clinicians can utilize PubCompare.ai to optimize their OHSS research by accessing a comprehensive database of protocols from published literature, preprints, and patents, and identifying the most reproducible and accurate protocols to enhance their studies.
These medications are used to induce the development of multiple follicles, which can lead to the overproduction of estrogen and the release of large amounts of fluid into the abdominal cavity.
OHSS can range from mild to severe, with symptoms including abdominal pain, nausea, vomiting, and rapid weight gain.
In severe cases, it can lead to life-threatening complications such as kidney failure and thrombosis.
Careful monitoring and management of ovarian stimulation is crucial to prevent and minimize the risk of OHSS.
Researchers and clinicians can utilize PubCompare.ai to optimize their OHSS research by accessing a comprehensive database of protocols from published literature, preprints, and patents, and identifying the most reproducible and accurate protocols to enhance their studies.
Most cited protocols related to «Ovarian Hyperstimulation Syndrome»
Abortion, Habitual
BLOOD
Body Weight
Disease, Chronic
Ejaculation
Endometrioma
Fibroid Tumor
Graafian Follicle
Hair Follicle
Menstrual Cycle
Menstrual Cycle, Proliferative Phase
Oocytes
Ovarian Hyperstimulation Syndrome
Ovarian Stimulation
Ovary
Ovum Implantation
Patients
Polycystic Ovary Syndrome
Pregnancy
Sperm
Sperm Injections, Intracytoplasmic
System, Endocrine
Ultrasonography
Uterus
Vaginal Smears
Woman
The guideline was developed according to a well-documented methodology that is universal to ESHRE guidelines (Vermeulen et al., 2017 ).
In short, 18 key questions were formulated by the Guideline Development Group (GDG) and structured in PICO format (Patient, Intervention, Comparison, Outcome). For each question, databases (PUBMED/MEDLINE and the Cochrane library) were searched from inception to 8 November 2018, with a limitation to studies written in English. From the literature searches, studies were selected based on the PICO questions, assessed for quality and summarized in evidence tables and summary of findings tables. The critical outcomes for this guideline are efficacy in terms of cumulative live birth rate (CLBR) per started cycle and LBR per started cycle, as well as safety in terms of moderate and/or severe OHSS. GDG meetings were organized where the evidence and draft recommendations were presented by the assigned GDG member and discussed until consensus was reached within the group.
Each recommendation was labelled as strong or conditional and a grade was assigned (Andrews et al., 2013 (link)) based on the strength of the supporting evidence (High ⊕⊕⊕⊕—Moderate ⊕⊕⊕ ⃝—Low ⊕⊕ ⃝ ⃝—Very low ⊕ ⃝ ⃝ ⃝). In the absence of evidence, the GDG formulated no recommendation or a good practice point (GPP) based on clinical expertise (Table I ).
The guideline draft and an invitation to participate in the stakeholder review were published on the ESHRE website. In addition, all relevant stakeholders received a personal invitation to review by e-mail. We received 168 comments from 39 reviewers, representing 21 countries, two national societies (British Fertility Society and working groups from ESHRE). All comments were processed by the GDG, either by adapting the content of the guideline and/or by replying to the reviewer. The review process was summarized in the review report, which is published on the ESHRE website (www.eshre.eu/guidelines ).
This guideline will be considered for update 4 years after publication, with an intermediate assessment of the need for updating 2 years after publication.
In short, 18 key questions were formulated by the Guideline Development Group (GDG) and structured in PICO format (Patient, Intervention, Comparison, Outcome). For each question, databases (PUBMED/MEDLINE and the Cochrane library) were searched from inception to 8 November 2018, with a limitation to studies written in English. From the literature searches, studies were selected based on the PICO questions, assessed for quality and summarized in evidence tables and summary of findings tables. The critical outcomes for this guideline are efficacy in terms of cumulative live birth rate (CLBR) per started cycle and LBR per started cycle, as well as safety in terms of moderate and/or severe OHSS. GDG meetings were organized where the evidence and draft recommendations were presented by the assigned GDG member and discussed until consensus was reached within the group.
Each recommendation was labelled as strong or conditional and a grade was assigned (Andrews et al., 2013 (link)) based on the strength of the supporting evidence (High ⊕⊕⊕⊕—Moderate ⊕⊕⊕ ⃝—Low ⊕⊕ ⃝ ⃝—Very low ⊕ ⃝ ⃝ ⃝). In the absence of evidence, the GDG formulated no recommendation or a good practice point (GPP) based on clinical expertise (
The guideline draft and an invitation to participate in the stakeholder review were published on the ESHRE website. In addition, all relevant stakeholders received a personal invitation to review by e-mail. We received 168 comments from 39 reviewers, representing 21 countries, two national societies (British Fertility Society and working groups from ESHRE). All comments were processed by the GDG, either by adapting the content of the guideline and/or by replying to the reviewer. The review process was summarized in the review report, which is published on the ESHRE website (
This guideline will be considered for update 4 years after publication, with an intermediate assessment of the need for updating 2 years after publication.
cDNA Library
Fertility
Needs Assessment
Ovarian Hyperstimulation Syndrome
Patients
Safety
Seventy-six women requiring IVF treatment for infertility at Hammersmith Hospital, London, UK, were screened for participation between August 2015 and May 2016. The inclusion criteria aimed to select women at high risk of OHSS: serum anti-Müllerian hormone (AMH) ≥40 pmol/L (≥5.6 ng/mL) or total antral follicle count (AFC) ≥23 (Lee et al., 2008 ; Jayaprakasan et al., 2012 (link)); age 18–34 years; early follicular phase serum follicle stimulating hormone (FSH) ≤12 iU/L; both ovaries intact; body mass index 18–29 kg/m2. Exclusion criteria were moderate/severe endometriosis and poor response to or ≥2 previous cycles of IVF treatment.
Ten patients were not eligible for inclusion and two patients withdrew consent prior to commencing the study protocol (Fig.1 ). A further two patients developed conditions requiring further management during the stimulation phase beyond the realms of the study protocol (e.g. hydrosalpinx) and were thus excluded prior to randomization. All treatment costs for the study cycle were covered by study participation. Sixty-two eligible patients underwent a single IVF treatment cycle and were randomized to receive either one (single; n = 31) or two doses (double; n = 31) of kisspeptin-54 to trigger oocyte maturation.
Ten patients were not eligible for inclusion and two patients withdrew consent prior to commencing the study protocol (Fig.
Full text: Click here
Endometriosis
Graafian Follicle
Human Follicle Stimulating Hormone
Index, Body Mass
KISS1 protein, human
Menstrual Cycle, Proliferative Phase
Mullerian-Inhibiting Hormone
Oocytes
Ovarian Hyperstimulation Syndrome
Ovary
Patients
Precipitating Factors
Serum
Sterility, Reproductive
Woman
The study was approved by an appropriately constituted ethic committee of the National Taiwan University Hospital (Institutional Review Board Number: 201507061RINB), and the written informed consents were obtained from all participants. This study was a retrospective cohort analysis involving women with an indication for COS in IVF or oocyte donation programs between January 2013 and September 2014. All patients were recruited from the Outpatient Department of the Stork Fertility Center (Hsinchu, Taiwan), and were counseled by fertility specialists regarding the stimulation protocol design before treatment began. A single dose of corifollitropin alfa followed by short-acting gonadotropin supplements was administered. Serum hormone levels (luteinizing hormone [LH], oestrodial [E2], progesterone [P4]) and stimulated follicle size were monitored during the follicular phase. Flexible GnRH antagonist administration based on the monitoring serum LH levels was used in the patients. Every patient was treated with corifollitropin alfa in only one IVF cycle. Patients with multiple IVF cycles were not included in this study. The harvested blastocysts were cryopreserved. All of the patients went through frozen-thawed blastocyst transfer(s) in the other menstrual cycle(s) to decrease the OHSS risk and to increase the success rate by optimizing the endometrial synchronization [14 ].
Full text: Click here
Blastocyst
Blastocyst Transfer
corifollitropin alfa
Dietary Supplements
Endometrium
Ethics Committees, Clinical
Ethics Committees, Research
Fertility
Freezing
Gonadorelin
Gonadotropins
Hormones
Luteinizing hormone
Menstrual Cycle
Menstrual Cycle, Proliferative Phase
Oocyte Donation
Outpatients
Ovarian Follicle
Ovarian Hyperstimulation Syndrome
Patients
Progesterone
Serum
Specialists
Treatment Protocols
Woman
Ascites
Ascitic Fluid
Complete Blood Count
Conservative Treatment
Culdocentesis
Diagnosis
Health Services, Outpatient
Inpatient
Liver Function Tests
Outpatients
Ovarian Hyperstimulation Syndrome
Paracentesis
Ultrasonics
Urinalysis
Vagina
Most recents protocols related to «Ovarian Hyperstimulation Syndrome»
Ovarian stimulation protocols included gonadotropin-releasing hormone (GnRH) agonist protocol, GnRH antagonist protocol, and progestin-primed ovarian stimulation (PPOS) protocol. Recombinant human chorionic gonadotropin (OVIDREL; Merck Serono, Darmstadt, Germany) or GnRH-a (Decapeptyl; Ferring, Saint-Prex, Switzerland) were administered in patients when two leading follicles reached 18 mm in diameter. Oocyte retrieval was performed at 36 h after recombinant human chorionic gonadotropin or GnRH-a triggered by transvaginal ultrasound-guided aspiration. Insemination method was selected according to the sperm count after sperm preparation. A morphologic score of cleavage-stage embryo was given based on the number of blastomeres, the homogeneous degree of blastomeres, and the degree of cytoplasmic fragmentation, which has been extensively described in our previous study (3 (link)). If a couple has two or more high-quality cleavage-stage embryos on day 3 of embryo culture, the embryos were selected and cultured to blastocyst stage. Blastocyst evaluation was performed according to the Gardner’s grading system (4 (link)).
For patients who underwent GnRH agonist protocol and GnRH antagonist protocol, one to two fresh embryos were transferred into the uterus of women free of OHSS, hydrosalpinx, intrauterine adhesion and high progesterone level (> 1.5 ng/ml) on the day of triggering, and then, the spare embryos were cryopreserved for the next FET. Patients who underwent PPOS protocol had to freeze all their embryos. The vitrified cryopreservation was conducted according to standard protocols, as previously described (5 (link)).
For patients who underwent GnRH agonist protocol and GnRH antagonist protocol, one to two fresh embryos were transferred into the uterus of women free of OHSS, hydrosalpinx, intrauterine adhesion and high progesterone level (> 1.5 ng/ml) on the day of triggering, and then, the spare embryos were cryopreserved for the next FET. Patients who underwent PPOS protocol had to freeze all their embryos. The vitrified cryopreservation was conducted according to standard protocols, as previously described (5 (link)).
Full text: Click here
Blastocyst
Blastomeres
Cleavage Stage, Ovum
Cryopreservation
Cytoplasm
Decapeptyl
Embryo
Freezing
Gonadorelin
Hair Follicle
Human Chorionic Gonadotropin
Insemination
Oocyte Retrieval
Ovarian Hyperstimulation Syndrome
Ovarian Stimulation
Ovidrel
Patients
PRIME protocol
Progesterone
Progestins
Sperm
Ultrasonography
Uterus
Woman
Controlled ovarian hyper-stimulation was performed using a short-acting GnRH agonist long protocol. Recombinant follicle-stimulating hormone (Merck Serono) was started at least 14 days after the downregulation of GnRH agonist for complete suppression of estradiol from 75 to 300IU/d. Ovulation was induced with human chorionic gonadotropin, and approximately 36 hours later, oocyte retrieval was performed under transvaginal ultrasonographic guidance. Fertilization was carried out using the standard IVF technique; if male infertility or fertilization failure occurred, oocytes were inseminated by ICSI. Embryo transfer was mostly performed using cleaving stage embryos (day 3). If a patient was at risk of ovarian hyperstimulation syndrome, the embryo was vitrified and transferred to a subsequent substituted cycle.
Down-Regulation
Embryo
Estradiol
Fertilization
Gonadorelin
Human Chorionic Gonadotropin
Human Follicle Stimulating Hormone
Male Infertility
Oocyte Retrieval
Ovarian Hyperstimulation Syndrome
Ovarian Stimulation
Ovulation
Ovum
Patients
Sperm Injections, Intracytoplasmic
Transfers, Embryo
Patients received IVF treatment according to the Fixed GnRH antagonist protocol [33 (link)]. On the second day of the menstrual cycle, recombinant human follicle-stimulating hormone 150–300 U (Gonal-F; Merck, Lyon, France; Puregon, MSD, Boulogne, France) was injected as Gn. Additionally, Gn doses were determined based on patient age, body mass index (BMI), bFSH, and bAFC. GnRH-ant (Cetrotide, Merck, Lyon, France) was administered from day 5 onward. Oocytes were then collected by follicular aspiration under ultrasound 34–36 h after triggering with GnRH-a (Triptoreline, Decapeptyl, Ipsen, France) or recombinant hCG (rhCG, Ovitrelle, Merck, Lyon, France). Eighteen hours after fertilization, embryo development was monitored daily and graded based on the number and size of blastomeres, fragmentation rate, multinucleation, and early densification. Notably, on the third day following oocyte retrieval, an embryo with seven–ten blastomeres was defined as high quality [34 (link)].
On day 3, one or two embryos in the best shape were selected and transferred using a soft Wallace catheter, or whole embryo freezing for vitrification was chosen to avoid ovarian hyperstimulation syndrome (OHSS), embryo–endometrium asynchrony, and other reasons.
For luteal support in advance of fresh embryo transfer (ET), we used an injection of progesterone (20 mg/branch, Zhejiang Xianju Pharmaceutical Co., Ltd.), 40 mg daily, and oral dydrogesterone tablets (10 mg/tablet, Abbott Healthcare Products B.V.), 30 mg per day, or progesterone vaginal sustained-release gel (90 mg/dose, Crinone VR 8%, Merck, Sherano, Switzerland). In addition, two bags of Chinese medicine, the Gushen Antai pills, were used daily. For the frozen embryo transfer (FET), the endometrial preparation protocols used before the FET were natural cycles, hormone replacement cycles, and stimulated cycles. Embryo transfer was performed after three days of progesterone supplementation. For natural cycles and hormone replacement cycles, progesterone supplementation was added, similar to the cycle of fresh embryo transfer. Stimulated cycle protocols for endometrial preparation were not supplemented with progesterone.
All patients completed an IVF cycle and then performed ET or FET until live birth or until the embryos in the current cycle were used up.
On day 3, one or two embryos in the best shape were selected and transferred using a soft Wallace catheter, or whole embryo freezing for vitrification was chosen to avoid ovarian hyperstimulation syndrome (OHSS), embryo–endometrium asynchrony, and other reasons.
For luteal support in advance of fresh embryo transfer (ET), we used an injection of progesterone (20 mg/branch, Zhejiang Xianju Pharmaceutical Co., Ltd.), 40 mg daily, and oral dydrogesterone tablets (10 mg/tablet, Abbott Healthcare Products B.V.), 30 mg per day, or progesterone vaginal sustained-release gel (90 mg/dose, Crinone VR 8%, Merck, Sherano, Switzerland). In addition, two bags of Chinese medicine, the Gushen Antai pills, were used daily. For the frozen embryo transfer (FET), the endometrial preparation protocols used before the FET were natural cycles, hormone replacement cycles, and stimulated cycles. Embryo transfer was performed after three days of progesterone supplementation. For natural cycles and hormone replacement cycles, progesterone supplementation was added, similar to the cycle of fresh embryo transfer. Stimulated cycle protocols for endometrial preparation were not supplemented with progesterone.
All patients completed an IVF cycle and then performed ET or FET until live birth or until the embryos in the current cycle were used up.
Full text: Click here
Blastomeres
Catheters
Cetrotide
Chinese
Contraceptives, Oral
Corpus Luteum
Crinone
Decapeptyl
Dydrogesterone
Embryo
Embryonic Development
Endometrial Cycle
Endometrium
Fertilization
Freezing
Gonadorelin
Gonal F
Human Follicle Stimulating Hormone
Index, Body Mass
Menstrual Cycle
Oocyte Retrieval
Ovarian Hyperstimulation Syndrome
Ovum
Patients
Pharmaceutical Preparations
Progesterone
Puregon
Tablet
Therapy, Hormone Replacement
Transfers, Embryo
Treatment Protocols
Triptorelin
Ultrasonography
Vaginal Gel
Vitrification
A total of 80 patients were initially included in the study between May 2022 and November 2022. Two patients were excluded from the study because of their use of medications different from the ones that were prescribed. Two other patients were excluded from the study because the couples refused ongoing treatment. Finally, this prospective study was carried out with a total of 76 women, who were treated at the assisted reproduction clinics of Etlik Zübeyde Hanım Women’s Health Training and Research Hospital of Ankara, Turkey. The study flow chart is given in Figure 1 . The research protocol was approved by the Local Ethical Committee (20.04.2022 2022/59). Patients who had a normal ovulatory function, semen analysis, and at the minimum a single patent fallopian tube were considered as having UEI and formed the study group (n = 40). The control group consisted of patients who were diagnosed with mild-moderate male factor infertility (n = 36).
Exclusion criteria included: a body mass index (BMI) > 35 kg/m2, age < 18 and > 40 years, a history of smoking, acute infection (within 14 days), chronic inflammatory autoimmune disease, any systemic or endocrine disease, multiple embryo transfers, frozen-thaw cycles, moderate or severe ovarian hyperstimulation syndrome (OHSS), use of any medication including vitamin supplements and couples with severe male infertility including azoospermia and severe oligoasthenospermia.
Demographic characteristics (maternal and paternal ages, BMI), number of cycles, total dosages of gonadotropin, duration of infertility and stimulation were recorded. Basal serum hormone levels on day three (D3) of the cycle, antral follicle count, number of retrieved and metaphase II (MII) oocytes, Grade 1-2-3 embryos [14 (link)], blastocyst quality scoring (BQS) [15 (link)], day of embryo transfer (ET), clinical pregnancy after fresh transfer cycles and serum MPO/PON ratio were recorded.
Exclusion criteria included: a body mass index (BMI) > 35 kg/m2, age < 18 and > 40 years, a history of smoking, acute infection (within 14 days), chronic inflammatory autoimmune disease, any systemic or endocrine disease, multiple embryo transfers, frozen-thaw cycles, moderate or severe ovarian hyperstimulation syndrome (OHSS), use of any medication including vitamin supplements and couples with severe male infertility including azoospermia and severe oligoasthenospermia.
Demographic characteristics (maternal and paternal ages, BMI), number of cycles, total dosages of gonadotropin, duration of infertility and stimulation were recorded. Basal serum hormone levels on day three (D3) of the cycle, antral follicle count, number of retrieved and metaphase II (MII) oocytes, Grade 1-2-3 embryos [14 (link)], blastocyst quality scoring (BQS) [15 (link)], day of embryo transfer (ET), clinical pregnancy after fresh transfer cycles and serum MPO/PON ratio were recorded.
Full text: Click here
Azoospermia
Blastocyst
Dietary Supplements
Disease, Chronic
Embryo
Endocrine System Diseases
Fallopian Tubes
Freezing
Gonadotropins
Graafian Follicle
Hormones
Index, Body Mass
Infection
Inflammation
Male Infertility
Metaphase
Mothers
Ovarian Hyperstimulation Syndrome
Ovulation
Ovum
Patients
Pharmaceutical Preparations
Pregnancy
Reproduction
Semen Analysis
Serum
Sterility, Reproductive
Transfers, Embryo
Vitamins
Woman
Controlled ovarian hyperstimulation (COH) was conducted with human chorionic gonadotropin (hCG). Gonadotropin-releasing hormone (GnRH) antagonists constitute a multiple-dose flexible regimen for the prevention of ovarian hyperstimulation syndrome (OHSS). Intracytoplasmic sperm injection (ICSI) was performed on metaphase II (MII) oocytes, and the resultant embryos were cultured to the blastocyst stage for biopsy. The biopsied blastocysts were cryopreserved for further embryo transfer cycles utilizing the vitrification procedure with individual tubes containing single blastocysts.
Full text: Click here
antagonists
Blastocyst
Embryo
Gonadorelin
Human Chorionic Gonadotropin
Metaphase
Ovarian Hyperstimulation Syndrome
Ovulation Induction
Ovum
Sperm Injections, Intracytoplasmic
Transfers, Embryo
Treatment Protocols
Vitrification
Top products related to «Ovarian Hyperstimulation Syndrome»
Sourced in Switzerland, Germany, Italy, France, United States, Spain, Netherlands, United Kingdom, Australia, Japan, Denmark, Brazil, China
Gonal-F is a recombinant human follicle-stimulating hormone (r-hFSH) produced by recombinant DNA technology. It is used as a fertility medication to stimulate follicular development and maturation in the ovary as part of an assisted reproductive technology (ART) program.
Sourced in Switzerland, Germany, Italy, United States, Brazil, Australia
Ovidrel is a laboratory product manufactured by Merck Group. It is a recombinant human chorionic gonadotropin (hCG) medication used for in vitro fertilization (IVF) procedures. Ovidrel is designed to trigger the final stage of egg maturation prior to ovulation.
Sourced in United Kingdom, Switzerland, Germany
Crinone is a medical device produced by Merck Group that is used for the administration of progesterone in gel form. It is designed to provide a controlled release of progesterone to support early pregnancy in certain medical conditions.
Sourced in Germany, Switzerland, United Kingdom, Spain, France, Netherlands, United States, Japan
Cetrotide is a laboratory product manufactured by Merck Group. It is a synthetic peptide that acts as a gonadotropin-releasing hormone (GnRH) antagonist. The core function of Cetrotide is to inhibit the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland.
Sourced in Germany, Switzerland, France, Italy, United Kingdom, Netherlands
Ovitrelle is a laboratory product manufactured by Merck Group. It is a gonadotropin-releasing hormone agonist used in in-vitro fertilization procedures.
Sourced in Germany, Switzerland
Triptorelin is a synthetic hormone used in laboratory settings. It functions as an agonist of the gonadotropin-releasing hormone (GnRH) receptor.
Sourced in Switzerland, Germany, United States, Denmark, Canada, Belgium, Spain, China, France, Sweden, United Kingdom
Menopur is a medication used in assisted reproductive technology (ART) procedures. It contains a mixture of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which are hormones that play a crucial role in the development and maturation of ovarian follicles.
Sourced in United States, Netherlands
Duphaston is a pharmaceutical product manufactured by Abbott. It is a synthetic progestogen used as a hormonal supplement.
Sourced in Germany, Switzerland
Decapeptyl is a lab equipment product manufactured by Ferring. It is a synthetic peptide that functions as a gonadotropin-releasing hormone (GnRH) agonist.
Sourced in United States
Novarel is a lab equipment product manufactured by Ferring. It is a sterile lyophilized powder used for the preparation of an injectable solution.
More about "Ovarian Hyperstimulation Syndrome"
Ovarian Hyperstimulation Syndrome (OHSS) is a serious complication that can occur during fertility treatments involving ovarian stimulation, such as those using medications like Gonal-F, Ovidrel, Crinone, Cetrotide, Ovitrelle, Triptorelin, Menopur, Duphaston, Decapeptyl, or Novarel.
These medications are used to induce the development of multiple follicles, which can lead to the overproduction of estrogen and the release of large amounts of fluid into the abdominal cavity.
OHSS can range from mild to severe, with symptoms including abdominal pain, nausea, vomiting, and rapid weight gain.
In severe cases, it can even lead to life-threatening complications like kidney failure and thrombosis.
Careful monitoring and management of ovarian stimulation is crucial to prevent and minimize the risk of OHSS.
Researchers and clinicians can utilize PubCompare.ai to optimize their OHSS research by accessing a comprehensive database of protocols from published literature, preprints, and patents.
This AI-driven platform helps identify the most reproducible and accurate protocols, enhancing the quality and productivity of OHSS studies.
By streamlining protocol discovery and selection, PubCompare.ai empowers researchers to conduct more effective and efficient investigations into this complex condition.
These medications are used to induce the development of multiple follicles, which can lead to the overproduction of estrogen and the release of large amounts of fluid into the abdominal cavity.
OHSS can range from mild to severe, with symptoms including abdominal pain, nausea, vomiting, and rapid weight gain.
In severe cases, it can even lead to life-threatening complications like kidney failure and thrombosis.
Careful monitoring and management of ovarian stimulation is crucial to prevent and minimize the risk of OHSS.
Researchers and clinicians can utilize PubCompare.ai to optimize their OHSS research by accessing a comprehensive database of protocols from published literature, preprints, and patents.
This AI-driven platform helps identify the most reproducible and accurate protocols, enhancing the quality and productivity of OHSS studies.
By streamlining protocol discovery and selection, PubCompare.ai empowers researchers to conduct more effective and efficient investigations into this complex condition.